Survival of Recombinant Monoclonal and Naturally-occurring Human Milk Immunoglobulins A and G Specific to Respiratory Syncytial Virus F Protein Across Simulated Human Infant Gastrointestinal Digestion
Overview
Affiliations
To help rationally design an antibody for oral administration, we examined how different isotypes (IgG, IgA and sIgA) with the same variable sequence affect antibody stability across digestion. We compared the degradation of recombinant palivizumab (IgG1), and recombinant IgA and sIgA versions of palivizumab spiked in human milk to the degradation of naturally-occurring anti-respiratory syncytial virus (RSV) sIgA/IgA and IgG in human milk from four donors across gastric and intestinal phases of an model of infant digestion via a validated RSV F protein ELISA. Palivizumab IgG and IgA formats were less stable than the sIgA version after complete simulated gastrointestinal digestion: palivizumab IgG, IgA and sIgA decreased across complete simulated gastrointestinal digestion by 55%, 48% and 28%, respectively. Naturally-occurring RSV F protein-specific IgG was stable across digestion, whereas naturally-occurring sIgA/IgA was stable in the gastric phase but decreased 33% in the intestinal phase of simulated digestion.
Complementary measurement of nontyphoidal specific IgG and IgA antibodies in oral fluid and serum.
Elias S, Muthumbi E, Mwanzu A, Wanjiku P, Mutiso A, Simon R Heliyon. 2023; 9(1):e12071.
PMID: 36704288 PMC: 9871079. DOI: 10.1016/j.heliyon.2022.e12071.
Pieri M, Maniori M, Shahabian L, Kanaan E, Paphiti-Demetriou I, Pipis S Nutrients. 2022; 14(16).
PMID: 36014873 PMC: 9415426. DOI: 10.3390/nu14163368.